Section Arrow
Quote
ANIX.NASDAQ
- Anixa Biosciences
Quotes are at least 15-min delayed:2026/02/03 15:45 EST
After Hours
Last
 --
-- (--)
Bid
--
Ask
--
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 3.06
+0.12 (+4.08%)
Day High 
3.07 
Prev. Close
2.94 
1-M High
3.58 
Volume 
123.98K 
Bid
3.06
Ask
3.07
Day Low
2.95 
Open
2.95 
1-M Low
2.9 
Market Cap 
98.14M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.11 
20-SMA 3.19 
50-SMA 3.68 
52-W High 5.4566 
52-W Low 2.331 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.34/-0.24
Enterprise Value
98.30M
Balance Sheet
Book Value Per Share
0.45
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.01
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc1.07+0.4989+87.36%-- 
After Hours -- -- --
SGMOSangamo Therapeutics0.39055-0.17735-31.23%-- 
After Hours -- -- --
RXRXRecursion Pharmaceuticals4.075-0.105-2.51%-- 
After Hours -- -- --
IBRXImmunityBio6.285+0.155+2.53%-- 
After Hours -- -- --
GERNGeron Corp1.505-0.035-2.27%-- 
After Hours -- -- --
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.